Comparison of circulating tumor cell numbers before and after treatment is predictive for overall survival in patients with metastatic castration-resistant prostate cancer; this comparison is more helpful than prostate-specific antigen detection, according to a recent study.
Access options
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1
de Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302–6309 (2008).
- 2
Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8, 329–340 (2008).
- 3
Okegawa, T., Nutahara, K. & Higashihara, E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J. Urol. 180, 1342–1347 (2008).
- 4
Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 7053–7058 (2007).
- 5
Ross, R. W. et al. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin. Cancer Res. 11, 5195–5198 (2005).
- 6
Ghossein, R. A. et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50, 100–105 (1997).
- 7
Allard, W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897–6904 (2004).
- 8
de Bono, J. S. et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 13, 3611–3616 (2007).
Author information
Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pantel, K., Riethdorf, S. Are circulating tumor cells predictive of overall survival?. Nat Rev Clin Oncol 6, 190–191 (2009). https://doi.org/10.1038/nrclinonc.2009.23
Issue Date:
Further reading
-
Tumor-cell detection, labeling and phenotyping with an electron-doped bifunctional signal-amplifier
Biosensors and Bioelectronics (2020)
-
Finding the perfect match between nanoparticles and microfluidics to respond to cancer challenges
Nanomedicine: Nanotechnology, Biology and Medicine (2020)
-
Tumor Hypoxia and Circulating Tumor Cells
International Journal of Molecular Sciences (2020)
-
EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy
PLOS ONE (2020)
-
Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer
Clinical Genitourinary Cancer (2019)